Jian Fang Selected Research

Platinum

4/2024	IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer.
2/2024	Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
12/2023	Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
1/2023	Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
1/2023	Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.
1/2023	Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.
8/2022	Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China.
1/2022	Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
7/2021	Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort study.
2/2021	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jian Fang Research Topics

Disease

59	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 06/2006
51	Neoplasms (Cancer) 05/2024 - 12/2002
22	Disease Progression 04/2024 - 01/2019
19	Neoplasm Metastasis (Metastasis) 02/2024 - 01/2006
13	Lung Neoplasms (Lung Cancer) 01/2023 - 11/2004
9	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2017
8	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2024 - 05/2015
7	Inflammation (Inflammations) 11/2023 - 10/2011
7	Infections 01/2022 - 01/2015
7	Adenocarcinoma of Lung 07/2021 - 04/2013
6	Carcinoma (Carcinomatosis) 10/2022 - 01/2018
6	Brain Neoplasms (Brain Tumor) 01/2022 - 12/2006
6	Hypertension (High Blood Pressure) 07/2021 - 05/2009
5	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2022
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 09/2006
5	Nausea 01/2021 - 11/2004
4	Atherosclerosis 12/2023 - 01/2018
4	Wounds and Injuries (Trauma) 11/2023 - 05/2006
4	Exanthema (Rash) 01/2022 - 11/2010
4	Vomiting 01/2021 - 11/2004
4	Fibrosis (Cirrhosis) 01/2017 - 12/2010
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2018
3	Adenocarcinoma 04/2013 - 06/2006
2	Metabolic Diseases (Metabolic Disease) 03/2024 - 01/2018
2	Diabetic Retinopathy (Retinopathy, Diabetic) 11/2023 - 08/2023
2	Ganglion Cysts (Ganglion) 11/2023 - 08/2023
2	Bone Resorption 03/2023 - 01/2019
2	Thymoma (Thymic Carcinoma) 01/2023 - 01/2019
2	Body Weight (Weight, Body) 10/2022 - 01/2016
2	Colitis 04/2022 - 01/2019
2	Proteinuria 07/2021 - 12/2018

Drug/Important Bio-Agent (IBA)

17	PlatinumIBA 04/2024 - 10/2012
16	Biomarkers (Surrogate Marker)IBA 01/2024 - 07/2017
14	Tyrosine Kinase InhibitorsIBA 12/2023 - 06/2006
13	Proteins (Proteins, Gene)FDA Link 02/2024 - 09/2006
10	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 11/2004
9	ErbB Receptors (EGF Receptor)IBA 06/2022 - 06/2006
8	Messenger RNA (mRNA)IBA 03/2023 - 09/2006
8	Bevacizumab (Avastin)FDA Link 01/2023 - 12/2019
7	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2021
7	Pemetrexed (MTA)FDA Link 01/2023 - 10/2012
5	CrizotinibIBA 02/2024 - 05/2016
5	Gefitinib (Iressa)FDA Link 01/2024 - 06/2006
5	RNA (Ribonucleic Acid)IBA 12/2023 - 10/2014
5	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 11/2004
5	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 10/2022 - 01/2019
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 11/2004
5	Long Noncoding RNAIBA 01/2020 - 12/2015
5	Gemcitabine FDA Link 01/2019 - 11/2004
4	atezolizumabIBA 04/2024 - 08/2022
4	Biosimilar PharmaceuticalsIBA 01/2023 - 12/2019
4	camrelizumabIBA 12/2022 - 01/2021
3	Docetaxel (Taxotere)FDA Link 04/2024 - 11/2018
3	ensartinibIBA 02/2024 - 01/2020
3	Anaplastic Lymphoma KinaseIBA 02/2024 - 01/2019
3	Etoposide (VP 16)FDA LinkGeneric 02/2024 - 10/2020
3	Retinaldehyde (Retinal)IBA 11/2023 - 04/2011
3	icotinibIBA 10/2023 - 04/2013
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2023 - 12/2005
3	B7-H1 AntigenIBA 05/2023 - 01/2021
3	Glucose (Dextrose)FDA LinkGeneric 03/2023 - 01/2019
3	rezivertinibIBA 01/2023 - 11/2022
3	sintilimabIBA 01/2023 - 01/2021
3	LigandsIBA 12/2022 - 07/2015
3	CholesterolIBA 07/2021 - 01/2016
3	Circulating Tumor DNAIBA 01/2021 - 01/2018
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2019 - 09/2014
3	Small Interfering RNA (siRNA)IBA 04/2019 - 02/2017
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 04/2016
3	tanshinoneIBA 10/2018 - 12/2010
2	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 01/2022
2	InflammasomesIBA 03/2024 - 11/2023
2	Caspase 3 (Caspase-3)IBA 08/2023 - 10/2018
2	AntioxidantsIBA 08/2023 - 07/2021
2	Oxidoreductases (Dehydrogenase)IBA 08/2023 - 01/2018
2	InterleukinsIBA 08/2023 - 04/2016
2	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 08/2023 - 10/2017
2	quinone (benzoquinone)IBA 08/2023 - 12/2010
2	Tartrate-Resistant Acid PhosphataseIBA 03/2023 - 05/2019
2	Phosphotransferases (Kinase)IBA 03/2023 - 10/2017
2	durvalumabIBA 01/2023 - 10/2020
2	aumolertinibIBA 01/2022 - 01/2022
2	Monoclonal AntibodiesIBA 01/2022 - 12/2019
2	EndostatinsIBA 07/2021 - 07/2016
2	Sirtuin 1IBA 03/2021 - 06/2017
2	CytokinesIBA 01/2021 - 12/2005
2	PhytochemicalsIBA 01/2021 - 01/2018
2	Emodin (Archin)IBA 01/2021 - 12/2005
2	Circular RNAIBA 01/2021 - 01/2019
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2020
2	anlotinibIBA 12/2020 - 01/2019
2	ATP-Binding Cassette Transporters (ABC Transporters)IBA 10/2020 - 01/2018

Therapy/Procedure

43	Drug Therapy (Chemotherapy) 04/2024 - 11/2004
35	Therapeutics 02/2024 - 01/2006
6	Radiotherapy 10/2020 - 12/2002
5	Immunotherapy 05/2024 - 10/2012
3	Chemoradiotherapy 03/2024 - 10/2020
2	Phacoemulsification 01/2024 - 04/2011
2	Induced Hyperthermia (Thermotherapy) 11/2023 - 01/2018
2	Neoadjuvant Therapy 01/2022 - 10/2020